PPARGC1A and breast carcinoma: Genetic and/or pharmacologic inhibition of PGC-1α suppresses ATP production, actin cytoskeleton remodeling, intravasation, extravasation, and cellular survival [142,148,149] and resensitizes breast cancer cells to standard of care therapies [150].